Stockscreener 앱 받기
1.54
0.65%
0.01
시간 외 거래:
1.53
-0.01
-0.65%
전일 마감가:
$1.53
열려 있는:
$1.5
하루 거래량:
165.83K
Relative Volume:
0.15
시가총액:
$95.89M
수익:
$2.82M
순이익/손실:
$-97.09M
주가수익비율:
-0.9675
EPS:
-1.5917
순현금흐름:
$-72.45M
1주 성능:
+0.65%
1개월 성능:
+0.65%
6개월 성능:
-31.56%
1년 성능:
+43.93%
1일 변동 폭
$1.48
$1.56
1주일 범위
$1.48
$1.70
52주 변동 폭
$0.8332
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
명칭
Pyxis Oncology Inc
전화
(617) 221-9059
주소
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.54 | 95.26M | 2.82M | -97.09M | -72.45M | -1.5917 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 재개 | Stifel | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2024-11-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-08-08 | 개시 | Stifel | Buy |
| 2024-05-07 | 재개 | Jefferies | Buy |
| 2024-02-09 | 개시 | BTIG Research | Buy |
| 2024-01-23 | 개시 | Leerink Partners | Outperform |
| 2023-09-05 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-02 | 개시 | BofA Securities | Neutral |
| 2021-11-02 | 개시 | Credit Suisse | Outperform |
| 2021-11-02 | 개시 | Jefferies | Buy |
모두보기
Pyxis Oncology Inc 주식(PYXS)의 최신 뉴스
PYXS SEC FilingsPyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Pyxis Oncology Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen - Defense World
Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen - MarketBeat
PYXS Technical Analysis & ETF Price Forecast - Intellectia AI
Will Pyxis Oncology Inc stock benefit from M A2025 Growth vs Value & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
PYXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Can Pyxis Oncology Inc. expand its profit marginsWeekly Trade Review & Low Drawdown Investment Ideas - mfd.ru
PYXS Should I Buy - Intellectia AI
Can Pyxis Oncology Inc. stock hit record highs againWeekly Risk Report & AI Powered Buy/Sell Recommendations - mfd.ru
Street Watch: Can Pyxis Oncology Inc sustain its profitabilityJuly 2025 News Drivers & Fast Gain Stock Tips - baoquankhu1.vn
PYXS PE Ratio & Valuation, Is PYXS Overvalued - Intellectia AI
Can Pyxis Oncology Inc. sustain its profitabilityJuly 2025 Fed Impact & Capital Protection Trade Alerts - mfd.ru
What catalysts could drive Pyxis Oncology Inc. stock higherJuly 2025 Summary & Risk Managed Trade Strategies - mfd.ru
Pyxis Oncology Announces Interim CEO Amid Leadership Transition - The Globe and Mail
Pyxis Oncology (PYXS) taps board member Thomas Civik as interim CEO in leadership shift - Stock Titan
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology appoints Thomas Civik as interim CEO By Investing.com - Investing.com Nigeria
Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026 - marketscreener.com
Pyxis Oncology names Thomas Civik as interim CEO - marketscreener.com
Pyxis Oncology Appoints Thomas Civik as Interim CEO - citybiz
Pyxis Oncology appoints Thomas Civik as interim CEO - Investing.com
Pyxis Oncology Announces Interim CEO Appointment and - GlobeNewswire
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Pyxis Oncology (NASDAQ:PYXS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Downgraded by Wall Street Zen to “Sell” - Defense World
Wall Street Zen Upgrades Pyxis Oncology (NASDAQ:PYXS) to “Hold” - Defense World
Wall Street Zen Upgrades Pyxis Oncology (NASDAQ:PYXS) to "Hold" - MarketBeat
Cancer drug developer Pyxis Oncology to join 2 November investor chats - Stock Titan
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - The Spec
Pyxis Oncology Reports Increased Losses Amid Development Focus - MSN
Returns Recap: How Pyxis Oncology Inc. stock compares to growth peers2025 Fundamental Recap & Low Volatility Stock Recommendations - ulpravda.ru
Aug Action: Will Pyxis Oncology Inc. stock benefit from automationPortfolio Value Report & Precise Swing Trade Alerts - ulpravda.ru
Will Pyxis Oncology Inc. stock benefit from automationJuly 2025 Decliners & Consistent Income Trade Ideas - Улправда
Will Pyxis Oncology Inc. stock gain from government policiesJuly 2025 Final Week & Fast Entry Momentum Trade Alerts - Улправда
Is Pyxis Oncology Inc. stock a dividend growth opportunity2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard - The Globe and Mail
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - RTTNews
Pyxis Oncology, Inc.Common Stock (NQ: PYXS - FinancialContent
Is Pyxis Oncology Inc. stock recession proofHead and Shoulders Patterns & Create Your Free Watchlist Instantly - ulpravda.ru
PYXS Stock Price, Forecast & Analysis | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - Chartmill
Pyxis Oncology (NASDAQ:PYXS) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Contrast - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
PYXS,RPTX Dividends - Finviz
Goosehead Insurance Inc 2OX Stock Analysis and ForecastMomentum Trading Signals & Exceptional Return Capital - earlytimes.in
Pyxis Oncology Inc (PYXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):